Search - tctmd.com

Displaying 801 - 820 of 980

Sort: Relevancy | Date

Presentation TCT 2013

Risk Stratified Antithrombin Therapy Before and During PCI: State-of-the-Art

Presenter: E. Magnus Ohman

October 31, 2013

Presentation TCT 2013

Risk Stratified Antiplatelet Therapy in ACS and During PCI: State-of-the-Art

Presenter: Harvey White

October 31, 2013

Presentation TCT 2013

Reversal Strategies Warfarin and the New Oral Anticoagulants: How Necessary, How Fast, How Safe, How Effective?

Presenter: Kurt Huber

October 31, 2013

Presentation TCT 2013

Prasugrel Rules: Simplest Second-Generation Agent with Fewest Side Effects!

Presenter: Michelle O'Donoghue

October 31, 2013

Presentation TCT 2013

Prasugrel Preloading in NSTEMI: ACCOAST Recap

Presenter: Gilles Montalescot

October 31, 2013

Presentation TCT 2013

Prasugrel for PCI in ACS and Stable CAD in Japan: PRASFIT-ACS and PRASFIT-Elective

Presenter: Masato Nakamura

October 31, 2013

Presentation TCT 2013

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Presenter: C. Michael Gibson

October 31, 2013

Presentation TCT 2013

Platelet Function Testing is of Clear Clinical Utility in Selected Patients

Presenter: Paul Gurbel

October 31, 2013

Presentation TCT 2013

Platelet Function and Genetic Testing are Currently Worthless

Presenter: Daniel Simon

October 31, 2013

News Conference News TCT 2013

OPTIMIZE: 3-Month DAPT Safe with ZES

October 31, 2013

Presentation TCT 2013

OPTIMIZE and ARTIC-INTERRUPTION: Perspectives on DAPT Duration after PCI

Presenter: Peter Wenaweser

October 31, 2013

Presentation TCT 2013

Optimal DAPT Duration Is Not Established: For Now Most Patients Should Stay on DAPT for at Least One Year!

Presenter: Edoardo Camenzind

October 31, 2013

Presentation TCT 2013

New Insights Into High Platelet Reactivity and the Existence of a Therapeutic Window: ADAPT-DES 2-Year Results

Presenter: Ajay Kirtane

October 31, 2013

Presentation TCT 2013

Mortality Trumps All: Ticagrelor for (Nearly) All!

Presenter: Michel Le May

October 31, 2013

News Conference News TCT 2013

HYBRID: Hybrid Revascularization Shows Safety, Effectiveness vs. CABG in Multivessel CAD

October 31, 2013

Presentation TCT 2013

GIANT: A Prospective Registry Study of CYP2C19 Genetic Profiling for Thienopyridine Management After Primary PCI in Acute Myocardial Infarction

Presenter: Bernard Chevalier

October 31, 2013

Presentation TCT 2013

Genetic Testing is of Clear Clinical Utility in Selected Patients

Presenter: Jessica Mega

October 31, 2013

News Conference News TCT 2013

FREEDOM: Insulin Status Affects Revascularization Outcomes in Diabetic Patients

October 31, 2013

Presentation TCT 2013

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Presenter: Fausto Feres

October 31, 2013

Presentation TCT 2013

Emerging Ticagrelor Data: Insights Into its Safety and Efficacy Profile

Presenter: Dimitrios Alexopoulos

October 31, 2013

Advertisement

Risk Stratified Antithrombin Therapy Before and During PCI: State-of-the-Art

Risk Stratified Antiplatelet Therapy in ACS and During PCI: State-of-the-Art

Reversal Strategies Warfarin and the New Oral Anticoagulants: How Necessary, How Fast, How Safe, How Effective?

Prasugrel Rules: Simplest Second-Generation Agent with Fewest Side Effects!

Prasugrel Preloading in NSTEMI: ACCOAST Recap

Prasugrel for PCI in ACS and Stable CAD in Japan: PRASFIT-ACS and PRASFIT-Elective

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Platelet Function Testing is of Clear Clinical Utility in Selected Patients

Platelet Function and Genetic Testing are Currently Worthless

OPTIMIZE: 3-Month DAPT Safe with ZES

OPTIMIZE and ARTIC-INTERRUPTION: Perspectives on DAPT Duration after PCI

Optimal DAPT Duration Is Not Established: For Now Most Patients Should Stay on DAPT for at Least One Year!

New Insights Into High Platelet Reactivity and the Existence of a Therapeutic Window: ADAPT-DES 2-Year Results

Mortality Trumps All: Ticagrelor for (Nearly) All!

HYBRID: Hybrid Revascularization Shows Safety, Effectiveness vs. CABG in Multivessel CAD

GIANT: A Prospective Registry Study of CYP2C19 Genetic Profiling for Thienopyridine Management After Primary PCI in Acute Myocardial Infarction

Genetic Testing is of Clear Clinical Utility in Selected Patients

FREEDOM: Insulin Status Affects Revascularization Outcomes in Diabetic Patients

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Emerging Ticagrelor Data: Insights Into its Safety and Efficacy Profile

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content